About Matthew

Matt advises public and private companies, private equity firms, financial institutions and alternative credit providers in various finance transactions and matters. His practice spans domestic and cross-border debt finance and debt capital markets transactions, including senior secured, junior lien and unsecured credit facilities; structured financings, such as royalty and revenue interest financings; convertible note offerings; acquisition financings; asset-based lending; high-yield and investment-grade bond offerings; and debt restructurings. He has experience across a range of industries, with a particular focus on financing life sciences and technology companies at all stages of development.

View full bio

Experience

Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals

Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals

September 2, 2025

Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

Read more

Related contacts

Charity Williams
Partner, San Diego
Emily Mason
Special Counsel, Santa Monica
Ken Rollins
Partner in Charge – San Diego, San Diego
Dylan Kornbluth
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Rachel Thorn
Of counsel, New York
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Matthew S. Scarano
Associate, San Diego
Max Levinbook
Associate, San Diego

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Emerging Companies
Tax
Life Sciences and Healthcare Regulatory
Life Sciences
Debt Finance
Biotechnology

MannKind to Acquire scPharmaceuticals for up to $360 Million

MannKind to Acquire scPharmaceuticals for up to $360 Million

August 25, 2025

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on its definitive merger agreement to acquire scPharmaceuticals for up to $360 million

Read more

Related contacts

Barbara Borden
Senior Counsel, San Diego
Rowook Park
Partner, San Diego
Julia Kim
Special Counsel, New York
Mischi a Marca
Partner, San Francisco
Adam J. Longenbach
Partner, New York
Matthew S. Scarano
Associate, San Diego
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Todd Gluth
Partner, San Diego
Eric Greig
Partner, Washington, DC
Asa Henin
Partner, San Diego
Phil Mitchell
Partner, New York
Alessandra Murata
Partner, Palo Alto
Stella Sarma
Partner, Brussels
Charity Williams
Partner, San Diego
Julia R. Brinton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Emily Mason
Special Counsel, Santa Monica
Randy Sabett
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
David Dalton
Associate, Santa Monica
Sharon Davidov
Associate, New York
Jameson Davis
Associate, Boston
Athina Gaki
Associate, Brussels
Tony P. Guan
Associate, Santa Monica
Josh Himmelstern
Associate, San Diego
Michelle Hunt
Associate
Wyatt Kernell
Associate, Colorado
Bomin Kim
Associate, New York
Allison Kutner
Associate, New York
Jacob R. Lahana
Associate, Santa Monica
Eileen Leman
Associate, Los Angeles
Walter Musgrave
Associate, San Diego
Joseph Perry
Associate, Reston
Allie Pilmer
Associate, San Diego
Breanna Qin
Associate, Palo Alto
Vittoria Rainone
Associate, San Diego
Bartholomäus Regenhardt
Associate, Brussels
Brittany K. Wightman
Associate, San Diego
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC

Related Practices & Industries

Mergers and Acquisitions
Life Sciences Corporate Partnering and Licensing
Debt Finance
Labor and Employment
Life Sciences and Healthcare Regulatory
Life Sciences
Compensation and Benefits
Capital Markets
Tax
Cyber/Data/Privacy
Antitrust and Competition
Healthcare

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

August 6, 2025

Cooley advised MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung diseases, on an up to $500 million strategic financing agreement with funds managed by Blackstone.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Adam J. Longenbach
Partner, New York
Asa Henin
Partner, San Diego
Matthew S. Scarano
Associate, San Diego
Margaret Barreto
Associate, San Francisco
Charles A. Watkins II
Associate, Santa Monica
Kavi Huded
Associate, New York
Jeffrey J. Tolin
Partner, New York
David Dalton
Associate, Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Stacey A. Bradford
Special Counsel, Washington, DC
Charity Williams
Partner, San Diego
Karen Tsai
Special Counsel, Washington, DC
Dr. Jon Cousin
Partner, Washington, DC
Dr. Jason Valentine
Associate, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Allison Kutner
Associate, New York
Phil Mitchell
Partner, New York
Wyatt Kernell
Associate, Colorado
Kimberly Nguyen
Special Counsel, Reston
Peter Crain
Special Counsel, Reston
Kristine Forderer
Partner, San Francisco

Related Practices & Industries

Debt Finance
Life Sciences
Healthcare
Tax
Life Sciences and Healthcare Regulatory
Compensation and Benefits
Life Sciences Corporate Partnering and Licensing
CFIUS
Patent Counseling and Prosecution
Cyber/Data/Privacy
Technology Transactions
Real Estate
Environmental

NeuroPace Secures up to $75 Million in Debt Financing

NeuroPace Secures up to $75 Million in Debt Financing

June 4, 2025

Cooley advised NeuroPace (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, on its $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility.

Read more

Related contacts

Matthew S. Scarano
Associate, San Diego
Charles A. Watkins II
Associate, Santa Monica
Jaime L. Chase
Partner, Washington, DC
Mark Weeks
Partner, Palo Alto

Related Practices & Industries

Debt Finance
Life Sciences
Medtech
Capital Markets
Healthcare
Biotechnology

Oberland Capital Invests up to $600 Million in Biohaven

Oberland Capital Invests up to $600 Million in Biohaven

April 28, 2025

Cooley advised Oberland Capital, a private investment firm committed to funding innovation across the global healthcare industry, on its agreement to invest up to $600 million in Biohaven (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Alexis Finkelberg Bortniker
Partner, San Diego
Dr. Jon Cousin
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Geoffrey Spolyar
Partner, Boston
Stacey A. Bradford
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Margaret Barreto
Associate, San Francisco
Wyatt Kernell
Associate, Colorado
Megan Mojabi (Flynn)
Associate, London
Matthew S. Scarano
Associate, San Diego
Stacy Colter
Senior Paralegal, New York

Related Practices & Industries

Debt Finance
Life Sciences
Life Sciences and Healthcare Regulatory
CooleyREG
Tax
Compensation and Benefits
Patent Counseling and Prosecution
Life Sciences Corporate Partnering and Licensing
View more

Admissions and credentials

California

New York

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.